344331-90-4

Basic information

• Product Name: (6-BROMO-2-PYRIDINYL)-CARBAMIC ACID,1,1-DIMETHYLETHYL ESTER
• Synonyms: 6-BROMO-2-TERT-BUTOXYCARBONYLAMINO-PYRIDINE;(6-BROMO-2-PYRIDINYL)-CARBAMIC ACID,1,1-DIMETHYLETHYL ESTER;tert-Butyl 6-bromopyridin-2-ylcarbamate;t-butyl N-(6-bromo-2-pyridinyl)carbamate;(6-BroMo-pyridin-2-yl)-carbaMic acid tert-butyl ester;2-(BOC-AMino)-6-broMopyridine;N-Boc-2-AMino-6-broMopyridine;Carbamic acid,N-(6-bromo-2-pyridinyl)-,1,1-dimethylethyl ester
• CAS NO: 344331-90-4
• Molecular Formula: C₁₀H₁₃BrN₂O₂
• Molecular Weight: 273.13
• Product Categories: pharmacetical
• Mol File: 344331-90-4.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 299.3 °C at 760 mmHg
• Flash Point: 134.8 °C
• Appearance: /
• Density: 1.454 g/cm³
• Vapor Pressure: 0.0012mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 11.89±0.70(Predicted)
• CAS DataBase Reference: (6-BROMO-2-PYRIDINYL)-CARBAMIC ACID,1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (6-BROMO-2-PYRIDINYL)-CARBAMIC ACID,1,1-DIMETHYLETHYL ESTER(344331-90-4)
• EPA Substance Registry System: (6-BROMO-2-PYRIDINYL)-CARBAMIC ACID,1,1-DIMETHYLETHYL ESTER(344331-90-4)

Safety Data

• Hazardous Substances Data: 344331-90-4(Hazardous Substances Data)

Usage

General Description

(6-Bromo-2-pyridinyl)-carbamic acid,1,1-dimethylethyl ester is a chemical compound with the formula C9H11BrN2O2. It is a bipyridyl herbicide, commonly used in agriculture to control a variety of broadleaf and grassy weeds. The compound works by inhibiting the enzyme acetolactate synthase, which is essential for the biosynthesis of the branched-chain amino acids valine, leucine, and isoleucine. This disruption ultimately leads to the death of the targeted weeds. However, the compound can be toxic to aquatic organisms and has the potential to bioaccumulate in the environment. Therefore, it is important to use this chemical with caution and in accordance with local regulations and best practices for its safe and effective use.

InChI:InChI=1/C10H13BrN2O2/c1-10(2,3)15-9(14)13-8-6-4-5-7(11)12-8/h4-6H,1-3H3,(H,12,13,14)

Upstream product

• 19798-81-3 2-Amino-6-bromopyridine 
• 34619-03-9 tert-butyldicarbonate 
• 75-44-5 phosgene 
• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 21190-87-4 6-bromo-pyridine-2-carboxylic acid 
• 870703-61-0 di-tert-butyl (6-bromo-2-pyridinyl)imidodicarbonate 

Downstream Products

• 762275-85-4 {6-[2,5-dimethoxy-4-(2-oxo-ethyl)-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-88-7 {6-[5-ethyl-2-methoxy-4-(2-oxo-ethyl)-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-89-8 {6-[4-(2-dimethylamino-ethyl)-2,5-dimethoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-84-3 {6-[4-(2-hydroxy-ethyl)-2,5-dimethoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-87-6 {6-[5-ethyl-4-(2-hydroxy-ethyl)-2-methoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 762275-90-1 {6-[4-(2-dimethylamino-ethyl)-5-ethyl-2-methoxy-phenyl]-pyridin-2-yl}-carbamic acid tert-butyl ester 
• 1257705-09-1 5-[4-(1,1-dioxothiomorpholin-4-ylmethyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine 
• 203321-83-9 tert-butyl 6-(hydroxymethyl)-2-pyridinylcarbamate 
• 1187837-10-0 tert-butyl (2-cyclohexylethyl)(6-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}pyridin-2-yl)carbamate 
• 1187836-72-1 N-(2-cyclohexylethyl)-6-{[({[3-(methylsulfanyl)phenyl](1-methyl-1H-tetrazol-5-yl)methylene}amino)oxy]methyl}pyridin-2-amine 
• 1187837-07-5 tert-butyl (2-cyclohexylethyl)[6-(hydroxymethyl)pyridin-2-yl]carbamate 
• 1187837-09-7 tert-butyl [6-(bromomethyl)pyridin-2-yl](2-cyclohexylethyl)carbamate 
• 959992-04-2 methyl 4-[3-({6-[(tert-butoxycarbonyl)(methyl)amino]pyridin-2-yl}methyl)azetidin-1-yl]-N-(2,6-dichlorobenzoyl)-L-phenylalaninate 
• 89026-81-3 (6-bromopyridin-2-yl)-isopropyl-amine 

Relevant articles and documents

PROCESSES FOR THE PREPARATION OF FILGOTINIB

The present invention relates to processes for the preparation of Filgotinib. The present invention relates to novel processes for the preparation of filgotinib. The present invention also relates to novel intermediates for the preparation of filgotinib.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES

The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.